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Hookworms are parasitic nematodes that have a
devastating impact on global health, particularly in
developing countries. We report a biochemical and
structural analysis of a peroxiredoxin from the hook-
worm Ancylostoma ceylanicum, AcePrx-1. Peroxire-
doxins provide antioxidant protection and act as
signaling molecules and chaperones. AcePrx-1 is
expressed in adult hookworms and can be inacti-
vated by 2,3-bis(bromomethyl)quinoxaline-1,4-diox-
ide (conoidin A). Conoidin A inactivates AcePrx-1
by alkylating or crosslinking the catalytic cyste-
ines, while maintaining the enzyme in the ‘‘locally
unfolded’’ conformation. Irreversible oxidation of
the resolving cysteine may contribute additional
inhibitory activity. A crystal structure of oxidized
AcePrx-1 reveals a disulfide-linked decamer. A helix
macrodipole near the active site increases the reac-
tivity of the catalytic cysteines to conoidin A. This
work demonstrates the promise of conoidin com-
pounds as probes to evaluate peroxiredoxins as
drug targets in human parasites.
INTRODUCTION
Hookworms are intestinal nematodes that rank as top agents of
global morbidity (Bungiro and Cappello, 2011; Hotez et al.,
2004). Human hookworm disease is caused by three hookworm
species: Necator americanus, Ancylostoma duodenale, and
Ancylostoma ceylanicum. Nearly one billion people suffer from
hookworm infection, which is characterized by iron deficiency
anemia, malnutrition, and suppression of host cellular immune
responses (Geiger et al., 2004; Loukas et al., 2005; Maizels
and Yazdanbakhsh, 2003). Hookworms and other soil-trans-
mitted nematode infections are most prevalent in children in
developing countries (Awasthi et al., 2003), although infection
occurs in all age groups and may exacerbate other commonChemistry & Biology 20, 991infectious diseases, including tuberculosis, malaria, and human
immunodeficiency virus (Bundy et al., 2000; Onyemelukwe and
Musa, 2001; Roussilhon et al., 2010). Although community-
based deworming programs may have short-term benefit, rapid
reinfection rates and declining efficacy of commonly used
anthelminthics raise doubts about the long-term value of chemo-
therapy as an effective means of disease control (Albonico et al.,
2004; Humphries et al., 2012; Keiser and Utzinger, 2008).
As blood feeding parasites, hookworms must handle the chal-
lenges of storage, sequestration, and detoxification of heme
groups. The components of the heme group are capable of
producing toxic reactive oxygen species (ROS), such as free
hydroxyl radicals and singlet oxygen molecules (Toh et al.,
2010). ROS are also released by host immune effector cells
such as macrophages, eosinophils, and neutrophils in their
response to hookworm infection (Donnelly et al., 2010; Hofmann
et al., 2002). Hookworms express at least two peroxiredoxins, a
family of peroxidases important for protection against ROS, pro-
tein folding (Tavender et al., 2010; Zito et al., 2010), and intracel-
lular signaling (reviewed in Hall et al., 2009; Winterbourn, 2008).
Certain peroxiredoxins, including PrxI from the human trema-
tode Schistosoma mansoni, also function as redox-regulated
ATP-independent chaperones (Jang et al., 2004; Saccoccia
et al., 2012). Peroxiredoxins are widely conserved across
eukaryotes (Figure 1). The active site of the ‘‘typical’’ class of
peroxiredoxins is formed at the intersubunit interface of homo-
dimers, which can assemble into rings of ten or twelve subunits
(Cao et al., 2011; Nelson et al., 2011; Schro¨der et al., 2000). A
catalytic peroxidatic cysteine residue reduces peroxide and
other ROS, resulting in hyperoxidation to sulfenic (-SOH), sulfinic
(-SO2H), or sulfonic acid (-SO3H) forms of the cysteine. The sul-
fenic acid form reacts with a second so-called resolving catalytic
cysteine residue across the dimer interface to form an intermo-
lecular disulfide bond. Oxidation to sulfinic acid can be repaired
by sulfiredoxin, while the sulfonic acid form is considered
irreversible (Cao et al., 2011; Nelson et al., 2011; Schro¨der
et al., 2000).
In humans, changes in peroxiredoxin expression levels are
associated with cancer, cardiovascular dysfunction, and neuro-
degeneration (Park et al., 2000). Hence, there is significant clin-
ical interest in human peroxiredoxin inhibitors. A cell-permeable–1001, August 22, 2013 ª2013 Elsevier Ltd All rights reserved 991
Figure 1. Sequence Alignment of Peroxiredoxin Sequences
GenBank IDs are JX124321 (Ancylostoma ceylanicum Prx-1), 47499100 (Haemonchus contortus Prx), 193204376 (Caenorhabditis elegans Prx-2), 32189392
(human PrxII), and 5453549 (human PrxIV). Secondary structure elements in the AcePrx-1 crystal structure are overlaid on the alignment.
Chemistry & Biology
Structure & Inhibition of a Hookworm Peroxiredoxinorganic compound, 2,3-bis(bromomethyl)quinoxaline-1,4-diox-
ide (conoidin A), has been shown to inhibit the hyperoxidation
activity of peroxiredoxin II from the apicomplexan parasite Toxo-
plasma gondii (TgPrxII), as well as human peroxiredoxins I and II
(Haraldsen et al., 2009). Conoidin A inhibits TgPrxII with an half-
maximal inhibitory concentration (IC50) of 23 mM by binding
covalently to the peroxidatic cysteine (Liu et al., 2010). More rele-
vant to the present study, conoidin A treatment of A. ceylanicum
eggs purified from the feces of infected hamsters as well as eggs
from field isolates of human hookworms resulted in a significant
inhibition of egg hatching, revealing the nematicidal activity of
conoidin A (Treger et al., 2013).
Here, we show that peroxiredoxin-1 from A. ceylanicum
(AcePrx-1) is expressed in adult worms and inactivated by con-
oidin A. Biophysical analyses and a crystal structure of oxidized
AcePrx-1 show that it forms a stable decamer, similar to human
peroxiredoxin IV (Cao et al., 2011). The active site architecture
increases the reactivity of the two catalytic cysteine residues
to conoidin A. Conoidin A inhibits AcePrx-1 by alkylating cyste-
ines, crosslinking the catalytic cysteines, or possibly oxidizing
one or both of the catalytic cysteines to an irreversible oxidation
state, while maintaining the enzyme in the so-called locally
unfolded (LU) conformation. This work demonstrates the poten-
tial applicability of conoidin compounds as chemical probes to
evaluate AcePrx-1 and related enzymes as possible drug targets
in A. ceylanicum and other human parasites.
RESULTS
AcePrx-1 Is Highly Expressed and Partially
Excreted/Secreted by Adult A. ceylanicum
Real-time PCR analysis of cDNA populations created from egg,
larval, and adult A. ceylanicum showed that the AcePrx-1 mRNA
transcript is present in much higher abundance in adult (female
or male) worms compared to egg (E) and (L1 or L3) larval stages992 Chemistry & Biology 20, 991–1001, August 22, 2013 ª2013 Elsev(37- and 24-fold higher, respectively; Figure 2A). Western blot
analysis of egg, larval, and adult stages of A. ceylanicum verified
this finding, revealing that AcePrx-1 is produced by adult worms
and is present in extracts (HEX) and excretory/secretory (ES)
products (Figure 2A). Protein levels in egg and larval stages
were below detection level with immunoblotting.
AcePrx-1 Is anActivePeroxidase Inhibited byConoidin A
The specific activity of recombinant AcePrx-1 peroxide meta-
bolism was determined to be 1.640 mmol min1 mg1 compared
to 1.182 mmol min1 mg1 for human PrxII (hPrxII) and
1.616 mmol min1 mg1 for human Prx-IV (hPrxIV). As expected,
a triple cysteine mutant (C49A/C73A/C170A) of AcePrx-1, which
lacked the peroxidatic and resolving cysteine residues, exhibited
no activity (Figure 2B). Conoidin A or its mono-brominated
analog, 2-(bromomethyl)-3-quinoxaline-1,4-dioxide (conoidin
B), inhibited the activity of wild-type AcePrx-1, hPrxII, and hPrxIV
in a dose-dependent manner up to the solubility limit of the com-
pounds with IC50 values of 374, 358, and 262 mM, respectively,
for conoidin A (Figures 2C and 2D). At inhibitor concentrations
above those tested in Figure 2D (120 mM), the compounds
precipitated, interfering with the assay. Conoidin A and conoidin
B inhibition profiles were similar for AcePrx-1, hPrxII, and hPrxIV,
indicating that these compounds do not have specificity for the
hookworm protein.
Conoidin A Hyperoxidizes the Catalytic Cysteines and
Reacts Covalently with All Three AcePrx-1 Cysteines
To determine whether AcePrx-1 reacts covalently with conoidin
A and whether the reaction occurs via the catalytic cysteines, we
analyzed wild-type and mutant AcePrx-1 proteins with SDS-
PAGE and mass spectrometry after treatment with conoidin A.
As expected for a 2-Cys peroxiredoxin, AcePrx-1 was mostly
dimeric in nonreducing SDS-PAGE and monomeric under
reducing conditions (Figures 3A and 3B). Three distinct bandsier Ltd All rights reserved
Figure 2. AcePrx-1 Is Expressed in Adult
Hookworms and Is Inhibited by Conoidin A
(A) Analysis of AcePrx-1 mRNA levels and
protein expression throughout the life cycle of
A. ceylanicum shows that AcePrx-1 is highly
expressed in adult hookworms compared to egg
(E), early larval stage (L1), or infectious larvae (L3).
(B) Specific activity of AcePrx-1 as determined by
monitoring the consumption of H2O2 in an iron-
based colorimetric assay. Activity of human per-
oxiredoxins-II and -IV are provided for comparison,
with the C49A/C73A/C170A AcePrx-1 mutant used
as a negative control.
(C and D) Inhibition of AcePrx-1, hPrxII, and hPrxIV
activity by conoidin A (C) and conoidin B (D). The
lack of inhibitory activity of conoidin B in the con-
centration range assayed may be due in part to the
low solubility of conoidin B.
Error bars represent the SEM of three experiments.
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ably corresponding to zero, one, and two disulfide bonds within
the dimer, respectively. Mutations at either or both of the active
site cysteine residues (Cys49, Cys170) rendered the protein pre-
dominantly monomeric (Figure 3A). A C-terminal truncation at
residue 171 (D171) did not affect this dimerization pattern. These
data confirm that AcePrx-1 forms disulfide-linked dimers via its
active site cysteine residues.
AcePrx-1 incubated for at least 30 min with a 3-fold molar
excess of conoidin A or conoidin B produced dimer bands in
SDS-PAGE (one faint dimer band for conoidin B and two strong
bands for conoidin A), in addition to the monomer band (Fig-
ure 3B). Mutation of Cys49, Cys170, or both resulted in a marked
reduction in the proportion of dimeric species in the presence of
conoidin under reducing conditions (Figure 3D). Low levels of
several discrete species of higher order oligomers were also
observed in the presence of conoidin A/B, ranging up to approx-
imately a decamer, even under reducing conditions (Figure 3D).
Dose-dependent formation of high-molecular-weight complexes
upon reaction with conoidin A has been observed previously with
hPrxII (Haraldsenetal., 2009).Small quantitiesof crosslinkedspe-
cies in theC49A/C73A/C170Amutant (Figure 3D)maybe attribut-
able to nonspecific covalent (or noncovalent SDS-resistant)
crosslinksby conoidin A to noncysteine residues. Together, these
data suggest that conoidin A covalently crosslinks AcePrx-1
mainly via the active site cysteines to form AcePrx-1 dimers.
To definitively identify the crosslinking sites within the dimers,
wild-type andmutant AcePrx-1 proteins were subjected to liquid
chromatography and electrospray ionization mass spectrometry
(LC-ESI-MS) with and without pretreatment with conoidin A orChemistry & Biology 20, 991–1001, August 22, 201conoidin B. Untreated wild-type AcePrx-1
produced two peaks, corresponding to
AcePrx-1 monomers and disulfide-linked
dimers, with masses of 22,960.0 and
45,920.0 Da, respectively (Figure 4A; Table
S1 available online). Additional peaks of
23,004.5 and 23,049.0Da for themonomer
and 46,009.0 and 46,179.0 for the dimer
represent different ionization states ofthe protein. Thus, LC-ESI-MS analysis confirms that wild-type
AcePrx-1 forms covalently linked dimers.
A 30 min incubation with conoidin A resulted in a 187–188 Da
quinoxaline dioxide (QDO) adduct on the monomer (Figure 4A;
Table S1; the 1-Da spread in themass shift is likely due to slightly
different charge states upon ionization). Themajor product was a
46,294.5 Da species, corresponding to two QDO adducts
bridging the peroxidatic and resolving cysteines within a dimer.
Displacement of a single bromine on conoidin A would have
resulted in a 268 Da adduct, which was not observed under
these conditions, suggesting that nucleophilic displacement of
the first bromine promotes displacement of the second. Peaks
corresponding to unmodified protein were not detected in the
conoidin A-treated samples. We conclude that the primary
mechanism of AcePrx-1 inactivation by conoidin A is covalent
crosslinking of the dimer.
Conoidin B reacted to wild-type AcePrx-1 to produce a 189-
Da adduct in LC-ESI-MS, although the alkylation reaction was
less efficient. Even after incubation for 1 hr, most of the protein
was unmodified. Data collected after an extended incubation
period of 6 hr produced noisier data and revealed multiple
species in solution. The major peak, with a mass shift of 377.5,
corresponded to alkylation at two sites by QDO adducts. A
mass shift of 221.0 Da suggests (hyper)oxidation of one or
both of the catalytic cysteines. Two additional minor peaks
were observed, corresponding to a single QDO adduct and
what was presumably a triple (528 Da) substitution containing
a mixture of QDO, quinoxaline monoxide (QMO), and/or qui-
noxaline (Qx) adducts. We note that we could not distinguish
between SO2H and 2,SOH. Although unexpected, the cysteine3 ª2013 Elsevier Ltd All rights reserved 993
Figure 3. SDS-PAGE Analysis Shows that Both Conoidin A and Conoidin B React with AcePrx-1
AcePrx-1 was purified under reducing conditions and desalted immediately prior to sample preparation.
(A)Wild-type andmutant AcePrx-1 under nonreducing conditions. Most of thewild-type protein is a disulfide-linked dimer. Neither a C73Amutation nor a deletion
of C-terminal residues 172–196 affect dimerization. Mutation of Cys49 or Cys170 renders the protein predominantly monomeric.
(B) Time course assay of wild-type AcePrx-1 reactivity with conoidin A and conoidin B. The time points are 0 hr, 0.5 hr, 1 hr, 3 hr, 6 hr, 24 hr, and 96 hr. The samples
were boiled in Laemmli buffer to quench reactivity and then run under reducing conditions. Dimeric species appear within only 0.5 hr and remain stable. After
96 hr, appreciable degradation was observed in these samples in the presence of conoidin A but not of conoidin B over the same duration. Faint bands cor-
responding to higher-order oligomers were observed after 96 hr.
(C) Reducing gel from dissolved crystals of the AcePrx-1(D171)/conoidin A complex. Conidin A covalently crosslinks AcePrx-1 into dimers. Traces of monomer
and higher order oligomers are visible.
(D) Reducing gel showing that conoidin A and conoidin B cause covalent (or noncovalent SDS-resistant) oligomerization of wild-type and mutant AcePrx-1 after
incubation for 24 hr. The appearance of higher-order oligomer bands in the C49A/C73A/C170A triple mutant suggests that side chains other than cysteine can
react with conoidin A nonspecifically and lead to crosslinking of AcePrx-1.
See also Table S1.
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N-oxide compounds to undergo successive one-electron reduc-
tion to mono-N-oxide or deoxygenated quinoxaline metabolites
(reviewed in Gonza´lez et al., 2007). This reaction is likely facili-
tated by oxidation of the highly reactive catalytic cysteine thiols.
While sulfenylation of Cys49 is part of the catalytic mechanism,
the observed oxidation of Cys170 should inhibit disulfide bond
formation with Cys49 and hence inactivate the enzyme. Hyper-
oxidation of the resolving cysteine (Cys170) therefore provides
a possible alternative mechanism to crosslinking for the inactiva-
tion of AcePrx-1 by conoidin A. However, hyperoxidized species
were only observed after several hours of incubation with conoi-
din, and these species were less abundant than crosslinked
species, so hyperoxidation is not expected to be the primary
mechanism of inhibition.994 Chemistry & Biology 20, 991–1001, August 22, 2013 ª2013 ElsevLC-ESI-MS data obtained from C-terminal tail deletion
mutants (D171 and C49A/C73A/D171) and the double- and
triple-cysteine mutants (C49A/C170A and C49A/C73A/C170A)
produced spectra with low noise levels (Figures 4B and 4C;
Figure S1), even after a 24-hr incubation with conoidin A or B.
Notably, while conoidin B treatment of the D171 sample resulted
in a slight shift toward themonomeric form, conoidin A treatment
resulted in a shift toward the dimer form with the masses of the
two predominant species shifted by 373 Da and 186 Da, respec-
tively. These mass shifts are consistent with crosslinks by one or
two quinoxaline dioxide (QDO) adducts. Because no changes in
mass were observed in the C49A/C170A double mutant (Fig-
ure 4C) and C49A/C73A/C170A triple mutant (Figure S1), we
conclude that the specific sites of modification are the peroxi-
datic and resolving cysteine residues. A 223 Da adduct wasier Ltd All rights reserved
Figure 4. Conoidin A and Conoidin B Covalently Modify AcePrx-1 by Alkylation or Crosslinking
LC-ESI-MS of wild-type and mutant AcePrx-1 are shown without pretreatment (left column), after treatment with conoidin B (middle column), and after treatment
with conoidin A (right column). The chemical composition of any adducts is shown schematically next to each peak in the spectra. Quinoxaline dioxide (QDO)
adducts are represented as two open hexagons. Filled hexagons indicate deoxygenation to themono-oxide. Each star represents the addition of a single oxygen
to the protein.
(A) Spectra for wild-type AcePrx-1 after a 6-hr treatment. Wild-type AcePrx-1 is predominately dimeric with a mass of 45,920 Da. Additional peaks represent the
monomer (22,960 Da) and various other protonation states, indicated by asterisks. Conoidin B treatment results in alkylation of up to three sites on the monomer,
while conoidin A treatment results in alkylation with a single QDO adduct, or crosslinking by two QDO adducts.
(legend continued on next page)
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A, corresponding to specific alkylation and hyperoxidation to
sulfinic acid of Cys170 (Figure S1B). A summary of the LC-ESI-
MS data is provided in Table S1. Together, the mass spec-
trometry data suggest that the primary mechanism of AcePrx-1
inactivation by conoidin A is covalent crosslinking of the active
site cysteines across the dimer interface, with hyperoxidation
of the resolving cysteine as a possible secondary mechanism.
Overall Structure of AcePrx-1
The crystal structure of AcePrx-1 determined in the absence of
reducing agent at 2.1 A˚ resolution (see Table 1 for crystallo-
graphic statistics) reveals a decamer assembled from five
AcePrx-1 dimers. The decamer has a ring-shaped (a2)5 architec-
ture with 52-point group symmetry (Figure 5). Size-exclusion
chromatography and multi-angle light scattering data show
that AcePrx-1 is also a decamer in solution (Figure S2). The over-
all structure of AcePrx-1 is similar to that of typical 2-Cys perox-
iredoxins. The most similar structure in the Protein Data Bank
(PDB) is human peroxiredoxin IV (PrxIV; PDB ID code 3TJB;
Cao et al., 2011). AcePrx-1 closely resembles PrxIV, with a
root-mean-square deviation (rmsd) of 0.60 A˚ for an all-atom
superposition of the two proteins. Like AcePrx-1, PrxIV also
forms a stable decamer in its oxidized state (Tavender et al.,
2008). In contrast, other typical 2-Cys peroxiredoxins dissociate
into dimers in the oxidized state, as demonstrated for example
for AhpC from Salmonella typhimurium (Wood et al., 2002).
Each monomer within the AcePrx-1 decamer has the same
overall fold as other oxidized typical 2-Cys peroxiredoxins,
with five a helices surrounding a central four-stranded b sheet
and a disordered C-terminal tail (Figure 5C). Residues 171–196
are disordered in each of the ten subunits. The rmsds of the
atom positions between pairs of monomers within the decamer
range from 0.22 to 0.36 A˚.
AcePrx-1 monomers within the decamer form two types of
intermolecular interfaces. The more extensive interface is
essentially identical to the head-to-tail dimer interface that is
conserved in all peroxiredoxins, many of which are obligate
dimers. Most of the contacts in this interface are formed by res-
idues 137–163. The b7 strands of the two subunits across the
interface form antiparallel b sheet contacts, thereby merging
the central b sheets of each subunit into an eight-stranded sheet
spanning the entire dimer (Figure 5C). The total surface area
buried in the dimer interface is 1,936 A˚2. As in other oxidized per-
oxiredoxins, the region surrounding the peroxidatic cysteine,
Cys49, is in the so-called LU conformation (Hall et al., 2009).
The loop bearing the resolving cysteine, Cys170, is in proximity
to Cys49 and has a high degree of thermal motion as evidenced
by the high temperature factors of the corresponding atoms (Fig-
ure S3). A notable feature of the dimer interface is a large cavity(B) The C49A/C170A double mutant does not react with conoidin A or conoidin
cysteine residues are the specific sites of modification in AcePrx-1.
(C) A C-terminal deletion mutant with residues 172–196 missing produces a ver
shown here).
(D) Proposed mechanism of conoidin A inhibition of AcePrx-1. A peroxiredoxin
undergoes successive SN2 reactions with a single molecule of conoidin A (i) to ge
oxidation of the thioether moieties by the N-oxide on conoidin A (ii), which produce
See also Figure S1.
996 Chemistry & Biology 20, 991–1001, August 22, 2013 ª2013 Elsevbetween strands b7 and helices a5 of the two subunits. The
cavity, which is also present in PrxIV, contains 10–12 structured
water molecules.
The second intermolecular interface within the AcePrx-1 dec-
amer, between the obligate dimers, involves helix a3 and buries
a substantial surface area of 1,276 A˚2, consistent with our obser-
vation that AcePrx-1 is a decamer in solution. The interface is
stabilized by a hydrogen bond between the side chain of
His107 and a backbone oxygen atom from the adjacent subunit,
and by p-stacking interactions between His107 side chains from
adjacent subunits. By stabilizing this second intermolecular
interface, these interactions may contribute to the stability of
the AcePrx-1 decamer in solution. In support of this hypothesis,
His107 is conserved in PrxIV but not in human PrxII (Figure 1),
which disassembles into dimers in the oxidized disulfide-bonded
form. AcePrx-1 contains an N-terminal histidine tag, and we note
that a similar tag was reported to stabilize the oligomeric form of
another oxidized peroxiredoxin (Cao et al., 2007). However,
AcePrx-1 containing a C-terminal histidine tag also formed sta-
ble decamers in dilute solutions, suggesting that the N-terminal
histidine tag alone does not confer stability to the decamer (Fig-
ures S2C and S2D).
Active Site Structure of AcePrx-1
The active site of peroxiredoxins undergoes a conformational
rearrangement during catalysis, cycling between a ‘‘fully folded’’
state during the peroxidation step and a ‘‘LU’’ state upon resolu-
tion of the Cys49 sulfenic acid by Cys170 to form a disulfide (Hall
et al., 2009). In the fully folded form, the peroxidatic cysteine thiol
is bound in a conserved pocket, whereas in the LU state the
end of helix a2, bearing the peroxidatic cysteine, and helix a6,
bearing the resolving cysteine, unwind to bring the two cysteines
in position for disulfide bonding. In the structure of AcePrx-1, the
enzyme is in theLU form (Figure 6), aswasexpectedbasedon the
oxidizing environment of the protein during purification and crys-
tallization. Adisulfidebond is clearly visible in the electron density
for two of the ten subunits (Figure 6A). In the remaining subunits,
electron density is lacking for the disulfide bond (Figure 6B), as
was also the case for PrxIV, either due to disorder of Cys170
and surrounding residues in the helixa6 region, or due to disulfide
bond reduction by electron flux during data collection.
Crystal Structure of Conoidin A Bound to AcePrx-1
To obtain a direct view of the inactivated enzyme, we determined
the crystal structure of AcePrx-1/conoidin A complex. Crystals of
the D171/conoidin A complex produced clearer electron density
in the active site region than crystals of the wild-type AcePrx-1/
conoidin A complex, suggesting that the disordered C-terminal
tail has a destabilizing effect on the active site region. The
D171/conoidin A complex was prepared from fully reducedB, even after treatment for 24 hr (shown here), suggesting that the catalytic
y similar set of adducts to wild-type AcePrx-1 (24-hr conoidin A/B treatment
dimer (orange and blue), drawn schematically in its fully folded conformation
nerate a 188-Da crosslinked adduct. An additional minor product is formed by
s the 220 Da covalent adduct observed in ourmass spectrometry experiments.
ier Ltd All rights reserved
Table 1. Data Collection and Refinement Statistics
Data Collection
Data set name Unliganded AcePrx-1 D171/conA complex
Space group P21 C2
Cell dimensions
a, b, c (A˚) 64.7, 146.3, 136.0 141.6, 141.7, 68.9
b () 95.2 98.5
Resolution (A˚)a 50.0–2.11
(2.15–2.11)
50.0–3.00
(3.11–3.00)
Rmerge (%)
a,b 6.3 (64.3) 7.9 (33.1)
I/sIa 20.6 (2.0) 13.0 (1.8)
Completeness (%)a 99.7 (95.5) 74.2 (15.0)e
Redundancya 4.0 (3.6) 3.6 (1.4)
Refinement and Model Quality
Resolution range (A˚) 50.0–2.11 50.0–3.00
No. reflections
(working set)
129,561 18,894
No. reflections
(test set)
7,228 994
Rwork/Rfree
c 19.5/21.4 18.6/20.0
No. atoms
Protein 13,404 6,761
Water 605 15
Ligand 0 27
Average B factors (residual after TLS refinementd)
Protein (A˚2) 29.7 89.6
Water (A˚2) 29.6 94.6
Ligand (A˚2) N/A 90.0
Rmsds from ideal values
Bond lengths (A˚) 0.005 0.005
Bond angles () 0.95 0.96
Ramachandran plot 97.8 97.5
Favored regions (%) 2.2 2.5
Outliers (%) 0.0 0.0
aHighest resolution shell is shown in parentheses.
bRmerge = ShklSi jIhkl,i < I > hklj / ShklSijIhkl,ij, where Ihkl is the intensity of a
reflection and < I > hkl is the average of all observations of the reflection.
cRfree, Rwork with 5% of Fobs sequestered before refinement.
dSee PDB entries for TLS refinement parameters.
eThe data were > 96% complete in each resolution shell up to 3.5 A˚.
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protein in the conoidin A complex had an essentially identical
structure to the unliganded structure, with an rmsd of 0.43 A˚ in
the Ca positions of the two structures. Although the 3.0 A˚ reso-
lution crystal structure of the complex contained only five
AcePrx-1 monomers in the asymmetric unit, decameric rings
are generated by the crystallographic symmetry. An Fo Fc elec-
tron density difference map revealed positive electron density
across the dimer interface that was connected to Cys49 in two
of the five subunits (Figures 6C and 6D). Based on our LC-ESI-
MS data, the electron density is expected to represent an
average of QDO, QMO, and Qx adducts. The first adduct,
between Cys49 of subunit B and Cys170 of subunit A, was
modeled as QMO (Figures 6C and 6D), because the oxygenChemistry & Biology 20, 991atom at the N4 N-oxide oxygen of QDO or Qx adducts caused
a steric clash with His91 of a symmetry-related AcePrx-1 mole-
cule. The second adduct, which connects Cys49 on subunit C to
Cys170 on subunit D, could be modeled as QDO without steric
clashes from neighboring molecules. The electron density was
weaker for the second adduct, which was refined with an occu-
pancy of 0.5. SDS-PAGE of dissolved AcePrx-1/conoidin A
crystals confirmed that the protein was fully crosslinked by the
inhibitor (Figure 3C). We conclude that the low apparent occu-
pancy is due to conformational flexibility (thermal disorder) of
the adduct. Moreover, the relative orientation of the twomodeled
adducts to the dimer dyad differs by nearly 90. Overall, the
different structure of the two conoidin A adducts, along with
the weak or absent electron density for adducts in four of five
subunits, suggest that the adducts have substantial conforma-
tional flexibility in the context of the locally unfolded active site.
DISCUSSION
Hookworms have devastating effects on global health and
new anthelminthic treatments are needed. Peroxiredoxins are
emerging as central players in parasite biology by performing
various essential functions in hookworms and other parasites
including antioxidant protection, intracellular signaling through
ROS, protein folding, and immunomodulation. The diversity of
these functions suggests that peroxiredoxins are promising
potential targets for antiparasite therapeutics.
We have shown here that AcePrx-1 is a peroxidase that is
partially secreted by adult A. ceylanicum hookworms. The crys-
tal structure of AcePrx-1 shows that it is most similar to human
PrxIV, despite the presence of an N-terminal extension including
a signal peptide in PrxIV but not AcePrx-1 (Cao et al., 2011). The
absence of the signal peptide in AcePrx-1 raises the possibility
that it is exported through a nonclassical secretory pathway,
as previously proposed for certain secretory products in the
helminthic parasite Fasciola hepatica (Robinson et al., 2009).
Notably, Prxs secreted by F. hepatica and S. mansoni have
recently been proposed to activate macrophages and promote
Th2 helper cell differentiation through expression of the chiti-
nase-like protein Ym1 (Donnelly et al., 2010). Whether secreted
AcePrx-1 also has immunomodulatory activity remains to be
determined.
Conoidin A, which was previously identified as an inhibitor of
TgPrxII, also inhibits AcePrx-1 consumption of peroxide in a
dose-dependent manner; the monobrominated analog conoidin
B does not show significant inhibition. Conoidins A and B inhibit
human peroxiredoxins hPrxII and hPrxIV with similar efficiency,
indicating that selectivity remains an issue to be addressed by
further chemical optimization of conoidin A or identification of
new, more selective ligands. In addition, before embarking on
compound optimization, it is necessary to prove that AcePrx-1
is essential and its cell function is not redundant.
Our mass spectrometry data show that conoidin A can inhibit
AcePrx-1 by alkylating or crosslinking the catalytic cysteines
(Figure 4D), and possibly by oxidizing the resolving cysteine.
We note that oxidation and alkylation (or crosslinking) are not
mutually exclusive. Conoidin A is expected to inhibit other
2-Cys peroxiredoxins, including mammalian homologs, by the
same mechanisms.–1001, August 22, 2013 ª2013 Elsevier Ltd All rights reserved 997
Figure 5. Crystal Structure of AcePrx-1
(A) Crystals of AcePrx-1 are colorless in the
absence of conoidin A.
(B) AcePrx-1 crystals grown in the presence of
conoidin A are yellow, suggesting that conoidin A
binds to the enzyme.
(C) AcePrx-1 adopts a fold similar to other per-
oxiredoxins. The most similar structure is human
Prx-4 (PDB Id code 3TJB). AcePrx-1 forms di-
mers principally via interstrand contacts to form
an eight-stranded b sheet. Dashed lines con-
nect the active site cysteines across the dimer
interface.
(D) Five AcePrx-1 dimers assemble into a deca-
mer in solution and in the crystal structure.
See also Figure S2.
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Structure & Inhibition of a Hookworm PeroxiredoxinThe pKa value of the peroxidatic cysteine ranges from 5 to 6 for
typical 2-Cys peroxiredoxins (Nelson et al., 2008; Ogusucu et al.,
2007; Peskin et al., 2007). Three conserved residues in the active
site have been proposed to lower the pKa of the peroxidatic
cysteine in other peroxiredoxins: arginine and threonine residues
that are presumed to stabilize the thiolate anion, and a proline
that shields the active site from water (Nelson et al., 2008; Ogu-
sucu et al., 2007; Peskin et al., 2007). In addition to these fea-
tures, analysis of the AcePrx-1 structure reveals that Cys49
and Cys170 are positioned at the positive end of the electrical
macrodipole of helix a2, providing an additional mechanism for
lowering the pKa (or, in the disulfide-linked form, increasing elec-
tronegativity) of these residues. We propose that the unusually
low pKa of the peroxidatic cysteine makes the side chain highly
reactive to conoidin A at physiologic pH by maintaining it in the
more nucleophilic thiolate state. Similarly, in the LU conforma-
tion, the resolving cysteine is also near the helix a2 macrodipole.
We conclude that the primary mechanism of inhibition of
AcePrx-1 is alkylation of either Cys49 or Cys170 or both (Fig-
ure 4D). Hyperoxidation of Cys170 cannot be ruled out as a
mechanism of inhibition but is likely to play a minor role under
physiologic conditions. Although sulfiredoxin (Srx) can repair sul-
finic acid oxidation of Cys49, the active site pocket in Srx specif-
ically accommodates only the Prx peroxidatic cysteine and a
molecule of ATP but not the resolving cysteine (Jo¨nsson et al.,
2009). Thus, oxidation of Cys170 to sulfenic (or sulfinic or sul-
fonic) acid abolishes its ability to regenerate the active enzyme
via intermolecular disulfide formation, and hyperoxidation of
Cys170 inactivates 2-Cys peroxiredoxins. Because these hyper-
oxidation and alkylation mechanisms can occur simultaneously,
their effects on enzyme activity are expected to be additive. This
is supported by the reduced inhibitory activity of a deoxygenated
conoidin A derivative against TgPrxII (Liu et al., 2010).
The crystal structure of AcePrx-1 bound to conoidin A pro-
vides a direct view of the conoidin A adduct crosslinking the
active site cysteines and validates our proposed mechanism
of conoidin inhibition. Oxidation of Cys49 by conoidin A, like
natural oxidation during catalysis (Hall et al., 2009), converts
the enzyme from the fully folded to the LU conformation. The
C-terminal tail (residues 171–196) becomes disordered in the
LU conformation, and the active site cysteines are brought998 Chemistry & Biology 20, 991–1001, August 22, 2013 ª2013 Elsevwithin disulfide bonding distance, whereas they are 4 A˚ further
apart in the fully folded state of hPrxIV. The C-terminal tail is
the region with the lowest sequence conservation across perox-
iredoxins from different species. A few conserved residues in
the C-terminal tail stabilize the active site cysteines in their
respective pockets in the fully folded state. The remaining
amino acid sequence is poorly conserved between human
and hookworm enzymes. Hence, a possible strategy for
increasing the species specificity of conoidin A for hookworm
peroxiredoxins is to functionalize the aromatic system of conoi-
din to preferentially react (or interact) with hookworm-specific
amino acids within the C-terminal tail. For example, an amine
reactive group could be appropriately placed to react with the
side chain amine of Lys178, which is specific to parasitic nem-
atode Prx sequences (Figure 1).
Our observation that AcePrx-1 is predominately expressed in
adult hookworms and not in egg or larval stages suggests that
inhibition of egg hatching by conoidin A (Treger et al., 2013)
may occur through inhibition of a protein other than AcePrx-1.
A second peroxiredoxin has been identified in A. ceylanicum,
but its expression pattern and biochemical activity have not yet
been studied. In validating peroxiredoxins as potential drug tar-
gets, it will be important to establish the specific functional roles
of each peroxiredoxin and of any related enzymes in each of the
developmental stages of the hookworm.
SIGNIFICANCE
In summary, our structural, biophysical, and biochemical
analysis of AcePrx-1 extends our understanding of the
mechanism of inhibition by conoidin A. We have shown
that conoidin A inactivates AcePrx-1 and its human ortho-
logs hPrxII and hPrxIV by alkylating or crosslinking the
catalytic cysteines, and that irreversible oxidation of the
resolving cysteine by conoidin A may contribute additional
inhibitory activity. Our crystal structure of oxidized AcePrx-1
shows that it forms stable disulfide-linked decamers like its
closest structural homolog hPrxIV, but unlike other 2-Cys
peroxiredoxins. A helix macrodipole near the active site in-
creases the reactivity of the catalytic cysteine residues to
conoidin A. The biochemical and structural characterizationier Ltd All rights reserved
Figure 6. The Active Site of AcePrx-1 in the Presence and Absence
of Conoidin A
(A) The structure of AcePrx-1 shows that the enzyme is in the LUd confor-
mation, with disulfide bonds between the peroxidatic and resolving cysteine
residues (Cys49 and Cys170, respectively) visible in two of the ten active sites
in the decameric asymmetric unit (subunit B and subunit C). Subunits A (blue)
and B (orange) are shown.
(B) In the remaining subunits (subunit A, subunits D–J), Cys170 is disordered
and electron density is lacking for the disulfide bond and helix a6 (subunit E is
in orange).
(C) Positive electron density is present in Fo  Fc maps (green) near the active
site cysteine residues of AcePrx-1 D171 cocrystallized with conoidin A. A
quinoxaline monoxide (QMO) adduct was modeled into the density and
refined. The view is rotated horizontally 90, then vertically 180 relative to
the view in (A).
(D) 2Fo  Fc map (blue) after refinement with the QMO adduct.
See also Figure S3.
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Structure & Inhibition of a Hookworm Peroxiredoxinof AcePrx-1 presented here provides a framework for the
validation of AcePrx-1 as a potential drug target and for
the identification of new candidate targets to combat hook-
worm infection. Moreover, this study suggests that conoidin
compounds could serve as chemical probes to explore the
emerging functions of peroxiredoxins in protein folding
and immunomodulation by human parasites.
EXPERIMENTAL PROCEDURES
Small Molecule Inhibitors
Conoidin A (2,3-bis(bromomethyl)-quinoxaline-1,4-dioxide) and its monobro-
minated analog conoidin B (2-(bromomethyl)-3-methylquinoxaline-1,4-diox-
ide) were kindly provided by the NIH Chemical Genomics Center or purchased
from Sigma-Aldrich.
Human Peroxiredoxin Proteins
The pQTEV-PRDX2 vector expressing hPrxII was purchased from Addgene
(plasmid #31338). hPrxII was purified using the same protocol as for
AcePrx-1. The N-terminal histidine purification tag was not cleaved for activity
assays. hPrxIV was purchased from United States Biological.Chemistry & Biology 20, 991Cloning of A. ceylanicum Peroxiredoxin 1
Complementary DNA (cDNA) was synthesized from total adult hookworm RNA
for use in PCR and RT-PCR reactions to amplify the AcePrx-1 sequence
and assess mRNA transcript abundance within developmental stages of
A. ceylanicum using the iScript cDNA synthesis kit (BioRad). The complete
open reading frame (ORF) ofAcePrx-1was amplified by PCR using oligonucle-
otide primers modified to contain an N-terminal histidine affinity purification
tag. The amplified gene was then subcloned into pET11 using NdeI and BamHI
restriction sites for expression in Escherichia coli. Cysteine mutants and
deletion mutants were generated by site-directed mutagenesis or overlap
extension PCR.
Real-Time PCR Analysis of AcePrx-1 Transcript Abundance
AcePrx-1 mRNA transcript levels were quantified by RT-PCR in cDNA popula-
tions obtained from eggs/L1, infectious L3, and adult male and female worms.
Primers amplifying an 100 base pair section of the ORF were generated with
Primer Express (Applied Biosystems). PCR amplification was performed in a
96-well format using optical tube strips and caps in an MJ Research DNA
Engine Opticon 2 PCR apparatus (BioRad) and iQ SYBR Green Supermix.
Reactions were cycled under the following conditions: 95C for 15 min, fol-
lowed by 15 s at 95C and 60 s at 60C. To confirm the absence of nonspecific
amplification in PCR reactions, control samples containing water substituted
for template were run and a melting point dissociation curve was generated
after every experiment to confirm the presence of a single PCR amplicon in
all experimental wells. All data were analyzed with Opticon Monitor version
3.1 (BioRad). A comparative cycle threshold method was used to obtain quan-
titative values for transcript levels in all samples.
Expression and Purification of Wild-Type and Mutant AcePrx-1
Proteins
The AcePrx-1 expression vectors were transformed into E. coli BL21 (DE3)
strain (Novagen) and cultured in Luria Broth supplemented with ampicillin at
0.1 mg/ml. Cells were induced during log-phase growth with 0.4 mM IPTG
for 4 hr at 37C. AcePrx-1 yield was 40–80 mg/l of cell culture.
AcePrx-1 was purified by nickel-affinity and size-exclusion chromatog-
raphy. Cells were lysed at 4C in lysis buffer, 50 mM HEPES pH 7.5, 0.1 M
NaCl, and 2mMDTT. After centrifugation for 40min at 40,000 rpm, the clarified
cell lysate was loaded onto a HisTrap HP nickel-affinity column (GE Health-
care). AcePrx-1 eluted off the column at 0.15 M imidazole pH 8.0. AcePrx-1
was further purified on a Superdex 200 size-exclusion column (GE Healthcare)
in 10mMHEPES pH 7.5, 0.1 MNaCl, and 10mMDTT. AcePrx-1 mutants were
purified using the same procedure. The N-terminal histidine tag was not
cleaved after purification.
Generation of a a-AcePrx-1 Antibody and Detection of AcePrx-1
in Hookworm Extracts
Groups of Golden Syrian hamsters (Mesocricetus auratus) were immunized
with 100 mg of rAcePrx-1 emulsified in Freund’s Complete adjuvant (Sigma).
The hamsters were boosted twice at 3-week intervals with an additional
50 mg of protein emulsified in Freund’s incomplete adjuvant (Sigma). Hamsters
were sacrificed and serumwas collected 10 days after the third and final vacci-
nation, and the IgG fraction was purified by Protein G affinity chromatography.
The maintenance and care of experimental animals complied with the National
Institutes of Health guidelines for the humane use of laboratory animals and
were approved by the Yale University Animal Care and Use Committee.
The presence of native AcePrx-1 in soluble protein extracts of A. ceylanicum
eggs (E), early larvae (L1), infectious larvae (L3), HEX, and ES was assessed
with immunoblot as previously described (Cho et al., 2007). Nitrocellulose
membranes containing native hookworm protein preparations were probed
with the hamster a-rAcePrx-1 IgG (1:3,000 dilution), followed by a secondary
horseradish peroxidase-conjugated goat a-hamster IgG (1:3,000 dilution).
Peroxiredoxin Activity Assay
Reduction of peroxide (H2O2) by recombinant AcePrx-1, hPrxII, and hPrxIV
wasmeasured using the PEROXsay assay kit (G-Biosciences), whichmonitors
the oxidation of ferrous (Fe2+) ions to ferric (Fe3+) ions by H2O2. Reactions were
performed at 25C in 50 mM sodium phosphate, pH 7.4, and 0.2 mM DTT.
After incubation of 2 mM peroxiredoxin with 40 mM H2O2 for 20 min, the–1001, August 22, 2013 ª2013 Elsevier Ltd All rights reserved 999
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Structure & Inhibition of a Hookworm Peroxiredoxinenzymatic reaction was quenched with the assay solution (containing D-sorbi-
tol, xylenol orange, ferric ammonium sulfate, and sulfuric acid) and incubated
for an additional 30min. Absorbance wasmeasured at 595 nm on amicroplate
reader (Biotek). A mutant lacking the active site cysteines was used as a nega-
tive control. A H2O2 titration standard curve in the absence of enzyme was
used to calculate the amount of H2O2 consumed in each assay. One activity
unit was defined as the amount of enzyme required to reduce 1 mmol of
H2O2 per minute.
Assays of peroxiredoxin inhibition by conoidin compounds were performed
as described above exceptwith 1Uof each enzymepre-incubatedwith various
concentrations of conoidin Aor conoidin B (0–120mM) for 30min at 25Cbefore
the addition of H2O2. The triple cysteine mutant was used to normalize each
concentration to 100% inhibition. All assays were performed in triplicate.
AcePrx-1 Crosslinking Assay
Wild-type and mutant AcePrx-1 proteins were desalted on a HiTrap desalting
column (GEHealthcare) to remove excess DTT and immediately reacted with a
3-fold molar excess of conoidin A for 0.5–96 hr at 25C. The final concentration
of AcePrx-1 in the crosslinking reaction was 0.8 g/l in 10mMHEPES and 0.1M
NaCl. The sample was analyzed with SDS-PAGE in the presence or absence of
0.2 M DTT.
LC-ESI-MS
Samples from the crosslinking assay (after various incubation times up to
24 hr) were injected on a Waters ACQUITY Ultraperformance liquid chroma-
tography system coupled to an ACQUITYUPLC Photodiode Array el detector.
Electrospray mass spectrograms were collected in the positive ion mode
and subsequently deconvoluted for molecular weight determination with
MASSLYNX software (Waters).
Crystallization and Structure Determination of AcePrx-1
Crystals were grown by hanging drop vapor diffusion from a 3.6 g/l solution of
AcePrx-1 at 12C. For each drop, 1 ml of AcePrx-1 in 10mMHEPES pH 7.5 and
0.1 M NaCl was mixed with 0.5 ml of the reservoir solution, 6%–8% PEG3350
and 0.1 MMES pH 6.0. Crystals were flash-frozen in liquid nitrogen in reservoir
solution supplemented with 20% glycerol. Crystallographic data were
collected at 100 K and processed with HKL (Otwinowski and Minor, 1997).
Crystals belonged to space group P21 with ten molecules per asymmetric
unit. The structure of AcePrx-1 was determined by molecular replacement
with Phaser (McCoy et al., 2007) using a single subunit of human PrxII (PDB
ID code 1QMV; Schro¨der et al., 2000) as the search model. The atomic coor-
dinates and temperature factors were refined with REFMAC5 (Murshudov
et al., 1997), initially with noncrystallographic symmetry restraints applied to
all ten subunits. The atomic model was improved with cycles of model building
with COOT (Emsley and Cowtan, 2004) followed by positional refinement.
Rigid-body motions of the ten subunits were modeled with REFMAC5 in terms
of TLS tensors for translation, libration, and screw-rotation (Winn et al., 2001).
Water molecules were added using an automated procedure in COOT and by
visual inspection.
Crystals of AcePrx-1 D171 in complex with conoidin A were obtained from
fully reduced D171 protein (1 g/l), which was desalted to remove excess
DTT and immediately reacted at a 3:1 molar ratio with conoidin A (150 mM).
The reaction was monitored to completion by mass spectrometry. Co-crystals
of the protein-inhibitor complex were grown by hanging drop vapor diffusion
as described above for unliganded AcePrx-1 but with 1%–2% PEG3350,
0.1 M MES pH 6.0 as the precipitant and reservoir solution supplemented
with 30% glycerol as the cryoprotectant. The conoidin A stock solution was
in 100% DMSO, and the final concentration of DMSO in protein solutions
was less than 0.1%. Crystals belonged to space group C2 with five molecules
per asymmetric unit. The structure was determined by molecular replacement
with Phaser using an AcePrx-1 pentamer as the search model. The atomic
coordinates were first refined in REFMAC as a rigid body, revealing additional
density at the C termini and connected to the peroxidatic cysteine residue on
two of the five subunits in 2Fo  Fc and Fo  Fc difference Fourier maps. The
quinoxaline dioxide adduct bearing sulfur thiols in place of the bromine atoms
was generated using PRODRG and input into SKETCHER to create the ligand
library description for use in refinement. See Table 1 for complete data collec-
tion and refinement statistics.1000 Chemistry & Biology 20, 991–1001, August 22, 2013 ª2013 ElseACCESSION NUMBERS
The GenBank accession number for the nucleotide and translated amino acid
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